cas 1689941-15-8|| where to buy (2S)-1-but-2-ynoylpyrrolidine-2-carboxylic acid

Nom du produit:(2S)-1-but-2-ynoylpyrrolidine-2-carboxylic acid

IUPAC Name:(2S)-1-(but-2-ynoyl)pyrrolidine-2-carboxylic acid

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1689941-15-8 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1689941-15-8; Formule moléculaire:C9H11NO3; Point de fusion:-; Code SMILES:CC#CC(=O)N1CCC[C@H]1C(O)=O; Densité:

: Numéro de catalogue:CM1077680; Poids moléculaire:181.19; Point d'ébullition:; N° Mdl:; Stockage:

: Pyrrolidines; Pyrrolidine, also known as tetrahydropyrrole, is a saturated five-membered heterocyclic ring, which is miscible with water. Pyrrolidine exists in many alkaloids and drug molecules, such as kappa opioids, antagonists of dopamine D4 receptors, and HIV reverse transcriptase inhibitors.

: Acalabrutinib; In positive interim analysis results from the phase 3 trial ECHO, acalabrutinib (Calquence; AstraZeneca) in combination with standard of care chemoimmunotherapy—bendamustine and rituximab—demonstrated both statistically significant and clinically meaningful improvement in progression-free survival (PFS) in adult patients with previously untreated mantle cell lymphoma (MCL) compared with standard of care alone. Acalabrutinib is a next-generation, selective inhibitor of Bruton tyrosine kinase (BTK) that binds covalently to BTK to hinder its activity. BTK signaling results in the activation of pathways that are necessary for B-cell proliferation, trafficking, chemotaxis, an adhesion within B cells.